FDA Fast-Tracks Zika Blood Tests with Class II Safety Nod
Published Date: 5/29/2025
Rule
Summary
The FDA is officially putting Zika virus blood test tools into a special safety group called Class II. This means these tests will have clear rules to keep them safe and working well, helping patients get better access to these important tools faster. This change affects companies making these tests and aims to cut down on red tape without costing extra time or money.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Zika serology reclassified to Class II
The FDA is classifying Zika virus serological reagents as Class II devices with special controls. The agency says this classification provides a reasonable assurance of the tests' safety and effectiveness. The action is intended to enhance patients' access to these tests by reducing regulatory burdens.
Reduced regulatory burden for test makers
The FDA says moving Zika virus serological reagents into Class II will reduce regulatory burdens for companies that make these tests. The classification aims to enhance access without adding extra time or cost for the industry.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in